LOXO Loxo Oncology, Inc.

+1.71  (2%)
Previous Close 80.17
Open 80.17
Price To book 8.77
Market Cap 2.14B
Shares 26,150,000
Volume 353,038
Short Ratio 24.83
Av. Daily Volume 388,975

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced 76% ORR at ASCO - June 3, 2017. Primary analysis by the end of 2017 with NDA filing late 2017 or early 2018.
Larotrectinib (LOXO-101)
Solid tumors that harbor a TRK fusion.

Latest News

  1. These Biotechs Are Leading The Sector To A 3-Month High Today
  2. Loxo Oncology Announces the Closing of its Follow-On Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
  3. Trump drug pricing order may be weeks away
  4. FDA to Clear Path for Drugs Aimed at Cancer-Causing Genes
  5. [$$] Loxo Strikes While the Biotech Iron is Hot
  6. Cancer's Big Infrastructure Problem
  7. Loxo Oncology Shares Rally, Despite Diluting Investors
  8. Loxo Oncology Prices Follow-On Offering of Common Stock
  9. Loxo Oncology launching secondary offering to fund drug research
  10. Loxo Oncology Announces Proposed Public Offering of Common Stock
  11. Excitement from ASCO: TG Thereapeutics, Loxo Oncology, and Bluebird Bio
  12. Precision Oncology Drug Shows Power Of Cancer Genomics
  13. Cramer Remix: What the dreaded rise in stocks, gold & Bitcoin means for your money
  14. Here Are Winners And Losers From Year's Biggest Cancer Meeting
  15. Why Navistar International, Loxo Oncology, and Helix Energy Solutions Jumped Today
  16. Here's Why Loxo Oncology Soared as Much as 58.5% Today
  17. Loxo stock soars on drug trial results: CEO
  18. Biotech Movers: Loxo, NewLink, BioCryst
  19. ASCO: Loxo Oncology shares up on cancer drug announcement...
  20. Loxo Oncology jumps 34% premarket on news of positive cancer drug trial